3-exo-(phenylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide | 1170674-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-exo-(phenylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide
• CAS: 1170674-32-4
• 化学式: C₂₁H₂₁F₃N₂O₃S
• 分子量: 438.471
• InChiKey: KAHBSCLGVNGHHA-IZZQQSIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  30.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.48
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  、 苯基[4-(三氟甲基)苯基]氨基甲酸酯 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.0h， 生成 3-exo-(phenylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of a Novel 3-Sulfonyl-8-azabicyclo[3.2.1]octane Class of Long Chain Fatty Acid Elongase 6 (ELOVL6) Inhibitors

  摘要：

  Long chain fatty acid elongase 6 (ELOVL6) catalyzes the elongation of long chain fatty acyl-CoAs and is a potential target for the treatment of metabolic disorders. The ultrahigh throughput screen of our corporate chemical collections resulted in the identification of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of ELOVL6 inhibitor 1a. Optimization of lead 1a led to the identification of the potent, selective, and orally available ELOVL6 inhibitor 1w.

  DOI：

  10.1021/jm900488k

文献信息

• Synthesis and Biological Evaluation of a Novel 3-Sulfonyl-8-azabicyclo[3.2.1]octane Class of Long Chain Fatty Acid Elongase 6 (ELOVL6) Inhibitors
  作者：Tsuyoshi Nagase、Toshiyuki Takahashi、Takahide Sasaki、Akira Nagumo、Ken Shimamura、Yasuhisa Miyamoto、Hidefumi Kitazawa、Maki Kanesaka、Ryo Yoshimoto、Katsumi Aragane、Shigeru Tokita、Nagaaki Sato

  DOI：10.1021/jm900488k

  日期：2009.7.23

  Long chain fatty acid elongase 6 (ELOVL6) catalyzes the elongation of long chain fatty acyl-CoAs and is a potential target for the treatment of metabolic disorders. The ultrahigh throughput screen of our corporate chemical collections resulted in the identification of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of ELOVL6 inhibitor 1a. Optimization of lead 1a led to the identification of the potent, selective, and orally available ELOVL6 inhibitor 1w.